Tiger Brokers

BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

Reuters
Jun 20
BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

June 20 (Reuters) - EMA's CHMP:

  • POSITIVE OPINION WAS ADOPTED FOR OGSIVEO, FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMOURS

  • NINTEDANIB VIATRIS GOT POSITIVE OPINION FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS, CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES

  • RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR REZDIFFRA, FOR TREATMENT OF ADULTS WITH NONCIRRHOTIC MASH

  • RECOMMENDED GRANTING MARKETING AUTHORISATION FOR AUSTEDO FOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE TARDIVE DYSKINESIA

  • POSITIVE OPINION FOR TENOFOVIR ALAFENAMIDE FOR TREATMENT OF ADULTS AND ADOLESCENTS INFECTED WITH HIV-1

  • STARTED RE-EXAMINATION OF ITS MARCH 2025 RECOMMENDATION NOT TO GRANT A MARKETING AUTHORISATION FOR KISUNLA ON JUNE 2

Source text: [ID:]

Further company coverage: SWTX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10